Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris.

Abstract

The effect of a liposomal preparation of beta-methasone dipropionate (0.039%, BDP) has been compared to that of a commercial propylene glycol-gel containing 0.064% BDP in a double-blind, randomized, paired trial lasting 14 d in 10 patients with atopic eczema and 10 patients with psoriasis vulgaris. In eczema, the liposome preparation tended to reduce erythema and scaling more than the conventional gel, the difference in the latter parameter being significant on Day 7. There was greater improvement of psoriasis on the side treated with the reference gel. Hence, liposome encapsulation of BDP may increase the antiinflammatory action but not the antiproliferative effect. Since inhibition of mitotic activity is linked to the atrophogenicity of topical corticosteroids, the results suggest that liposome encapsulation may improve the benefit-risk ratio in eczema.

• Authors: H C Korting, H Zienicke, M Schäfer-Korting, O Braun-Falco
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 39 Issue 4 Pg. 349-51 ( 1990) ISSN: 0031-6970 [Print] Germany
• PMID: 2076716 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Drug Carriers
• Liposomes
• betamethasone-17,21-dipropionate
• Betamethasone

Topics

• Adult
• Betamethasone (administration & dosage, analogs & derivatives, pharmacology)
• Dermatitis, Atopic (drug therapy)
• Double-Blind Method
• Drug Carriers
• Female
• Humans
• Liposomes
• Male
• Psoriasis (drug therapy)